Electronic medical records can be used to emulate target trials of sustained treatment strategies

被引:79
作者
Danaei, Goodarz [1 ,2 ]
Garcia Rodriguez, Luis Alberto [3 ]
Fernandez Cantero, Oscar [3 ]
Logan, Roger W. [2 ]
Hernan, Miguel A. [2 ,4 ,5 ]
机构
[1] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA
[2] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, 655 Huntington Ave, Boston, MA 02115 USA
[3] Ctr Espanol Invest Farmacoepidemiol, Madrid, Spain
[4] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
[5] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA USA
基金
美国医疗保健研究与质量局;
关键词
Comparative effectiveness; Secondary prevention; Confounding; Medication adherence; Survival analysis; Electronic health records; CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; RANDOMIZED-TRIALS; STATINS; METAANALYSIS; PREVENTION; SURVIVAL; EXPOSURE; DESIGNS; COHORT;
D O I
10.1016/j.jclinepi.2017.11.021
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: To emulate three target trials: single treatment vs. no treatment, joint treatment vs. no treatment, and head-to-head comparison of two treatments, we explain how to estimate the observational analogs of intention-to-treat and per-protocol effects, using hazard ratios and survival curves. For per-protocol effects, we describe two methods for adherence adjustment via inverse-probability weighting. Study Design and Setting: Prospective observational study using electronic medical records of individuals aged 55-84 with coronary heart disease from >500 practices in the United Kingdom between 2000 and 2010. Results: The intention-to-treat mortality hazard ratio (95% confidence interval) was 0.90 (0.84, 0.97) for statins vs. no treatment, 0.88 (0.73, 1.06) for statins plus antihypertensives vs. no treatment, and 0.91 (0.77, 1.06) for atorvastatin vs. simvastatin. When censoring non adherent person-times, the per-protocol mortality hazard ratio was 0.74 (0.64, 0.85) for statins vs. no treatment, 0.55 (0.35, 0.87) for statins plus antihypertensives vs. no treatment, and 1.13 (0.88, 1.45) for atorvastatin vs. simvastatin. We estimated per-protocol hazard ratios for a 5-year treatment using different dose-response marginal structural models and standardized survival curves for each target trial using intention-to-treat and per-protocol analyses. Conclusion: When randomized trials are not available or feasible, observational analyses can emulate a variety of target trials. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:12 / 22
页数:11
相关论文
共 25 条
[1]  
[Anonymous], 1986, Statist. Sci.
[2]   Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention - The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study [J].
Athyros, VG ;
Papageorgiou, AA ;
Mercouris, BR ;
Athyrou, VV ;
Symeonidis, AN ;
Basayannis, EO ;
Demitriadis, DS ;
Kontopoulos, AG .
CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (04) :220-228
[3]   Using fractional polynomials to model the effect of cumulative duration of exposure on outcomes: applications to cohort and nested case-control designs [J].
Austin, Peter C. ;
Park-Wyllie, Laura Y. ;
Juurlink, David N. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (08) :819-829
[4]   Debate about Funding Comparative-Effectiveness Research. [J].
Avorn, Jerry .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (19) :1927-1929
[5]   Constructing inverse probability weights for marginal structural models [J].
Cole, Stephen R. ;
Hernan, Miguel A. .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2008, 168 (06) :656-664
[6]   Interpretation of the evidence for the efficacy and safety of statin therapy [J].
Collins, Rory ;
Reith, Christina ;
Emberson, Jonathan ;
Armitage, Jane ;
Baigent, Colin ;
Blackwell, Lisa ;
Blumenthal, Roger ;
Danesh, John ;
Smith, George Davey ;
DeMets, David ;
Evans, Stephen ;
Law, Malcolm ;
MacMahon, Stephen ;
Martin, Seth ;
Neal, Bruce ;
Poulter, Neil ;
Preiss, David ;
Ridker, Paul ;
Roberts, Ian ;
Rodgers, Anthony ;
Sandercock, Peter ;
Schulz, Kenneth ;
Sever, Peter ;
Simes, John ;
Smeeth, Liam ;
Wald, Nicholas ;
Yusuf, Salim ;
Peto, Richard .
LANCET, 2016, 388 (10059) :2532-2561
[7]   Statins and Risk of Diabetes An analysis of electronic medical records to evaluate possible bias due to differential survival [J].
Danaei, Goodarz ;
Rodriguez, Luis A. Garcia ;
Cantero, Oscar Fernandez ;
Hernan, Miguel A. .
DIABETES CARE, 2013, 36 (05) :1236-1240
[8]   Observational data for comparative effectiveness research: An emulation of randomised trials of statins and primary prevention of coronary heart disease [J].
Danaei, Goodarz ;
Garcia Rodriguez, Luis A. ;
Fernandez Cantero, Oscar ;
Logan, Roger ;
Hernan, Miguel A. .
STATISTICAL METHODS IN MEDICAL RESEARCH, 2013, 22 (01) :70-96
[9]   Bias in Observational Studies of Prevalent Users: Lessons for Comparative Effectiveness Research From a Meta-Analysis of Statins [J].
Danaei, Goodarz ;
Tavakkoli, Mohammad ;
Hernan, Miguel A. .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2012, 175 (04) :250-262
[10]   Making Observational Studies Count Shaping the Future of Comparative Effectiveness Research [J].
Dreyer, Nancy A. .
EPIDEMIOLOGY, 2011, 22 (03) :295-297